Short Interest in Bionomics Limited (NASDAQ:BNOX) Drops By 39.4%

by · The Cerbat Gem

Bionomics Limited (NASDAQ:BNOX – Get Free Report) was the target of a significant drop in short interest during the month of September. As of September 30th, there was short interest totalling 73,000 shares, a drop of 39.4% from the September 15th total of 120,400 shares. Based on an average trading volume of 964,700 shares, the short-interest ratio is currently 0.1 days.

Bionomics Trading Up 3.6 %

NASDAQ BNOX traded up $0.01 during mid-day trading on Friday, hitting $0.28. The company’s stock had a trading volume of 47,473 shares, compared to its average volume of 449,124. Bionomics has a 52-week low of $0.25 and a 52-week high of $4.73. The stock’s fifty day simple moving average is $0.56 and its two-hundred day simple moving average is $0.76.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Bionomics in a report on Thursday, August 1st.

Get Our Latest Stock Analysis on Bionomics

Institutional Trading of Bionomics

A hedge fund recently bought a new stake in Bionomics stock. Armistice Capital LLC acquired a new position in shares of Bionomics Limited (NASDAQ:BNOX – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned approximately 15.03% of Bionomics at the end of the most recent reporting period. 15.90% of the stock is owned by hedge funds and other institutional investors.

Bionomics Company Profile

(Get Free Report)

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.

Featured Articles